A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) (BrigHTN)
Resistant Hypertension

About this trial
This is an interventional treatment trial for Resistant Hypertension
Eligibility Criteria
Inclusion Criteria:
- Is on a stable regimen of ≥ 3 antihypertensive agents (one of which is a diuretic) for at least 4 weeks prior to randomization;
- Be at least 70% compliant to their anti-hypertensive medication regimen;
- Has a seated BP ≥ 130/80 mmHg;
- Agrees to comply with the contraception and reproduction restrictions of the study; and
- Able to understand and willing to comply with all study visits, procedures, restrictions, and provide written informed consent according to institutional and regulatory guidelines.
Exclusion Criteria:
- Has a seated SBP ≥ 180 mmHg or DBP ≥ 110 mmHg;
- Has a body mass index (BMI) > 40 kg/m2;
- Has an upper arm circumference < 7 or > 17 inches;
- Has been on night shifts at any time during the 4 weeks before Screening;
- Is using a beta blocker for any primary indication other than systemic hypertension (eg, migraine headache);
- Is not willing or not able to discontinue an MRA or a potassium sparing diuretic as part of an existing antihypertensive regimen;
- Is not willing or not able to discontinue taking a potassium supplement;
- Has documented estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m2
- Has known and documented New York Heart Association stage III or IV chronic heart failure
- Has had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure within 6 months before Screening;
- Has known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease diagnosed from a prior echocardiogram;
- Major cardiac surgery (eg, CABG, valve replacement), peripheral arterial bypass surgery, or PCI within 6 months before Screening;
- Has chronic permanent atrial fibrillation;
- Has uncontrolled diabetes with glycosylated hemoglobin > 9.5% at Screening;
- Has planned dialysis or kidney transplant during the course of this study;
- Potassium < 3.5 mEq/L;
- Potassium > 5.0 mEq/L;
- Is positive for HIV antibody, hepatitis C virus RNA, or hepatitis B surface antigen;
- Has typical consumption of ≥14 alcoholic drinks weekly.
Sites / Locations
- CinCor Site 16
- CinCor Site 38
- CinCor Site 61
- CinCor Site 90
- CinCor Site 82
- CinCor Site 91
- CinCor Site 25
- CinCor Site 73
- CinCor Site 36
- CinCor Site 34
- CinCor Site 14
- CinCor Site 28
- CinCor Site 19
- CinCor Site 32
- CinCor Site 44
- CinCor Site 66
- CinCor Site 56
- CinCor Site 30
- CinCor Site 13
- CinCor Site 74
- CinCor Site 22
- CinCor Site 20
- CinCor Site 1
- CinCor Site 84
- CinCor Site 70
- CinCor Site 89
- CinCor Site 94
- CinCor Site 5
- CinCor Site 9
- CinCor Site 23
- CinCor Site 88
- CinCor Site 71
- CinCor Site 11
- CinCor Site 15
- CinCor Site 81
- CinCor Site 49
- CinCor Site 35
- CinCor Site 58
- CinCor Site 54
- CinCor Site 29
- CinCor Site 24
- CinCor Site 69
- CinCor Site 64
- CinCor Site 75
- CinCor Site 65
- CinCor Site 52
- CinCor Site 21
- CinCor Site 92
- CinCor Site 50
- CinCor Site 45
- CinCor Site 47
- CinCor Site 31
- CinCor Site 4
- CinCor Site 55
- CinCor Site 59
- CinCor Site 6
- CinCor Site 7
- CinCor Site 86
- CinCor Site 43
- CinCor Site 39
- CinCor Site 97
- CinCor Site 42
- CinCor Site 27
- CinCor Site 80
- CinCor Site 79
- CinCor Site 87
- CinCor Site 2
- CinCor Site 72
- CinCor Site 46
- CinCor Site 93
- CinCor Site 37
- CinCor Site 85
- CinCor Site 48
- CinCor Site 3
- CinCor Site 77
- CinCor Site 8
- CinCor Site 33
- CinCor Site 76
- CinCor Site 41
- CinCor Site 51
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
CIN-107 0.5mg
CIN-107 1mg
CIN-107 2mg
Placebo
Subjects received CIN-107 0.5 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
Subjects received CIN-107 1 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
Subjects received CIN-107 2 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
Subjects received placebo tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.